Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + lenvatinib + oxaliplatin + leucovorin + 5-fluorouracil
- Development stage
- Phase 3
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Hepatic Arterial Infusion
01
Overview
Toripalimab-Sun Yat-sen University-hepatocellular carcinoma refers to a specific combination therapy regimen investigated by Sun Yat-sen University Cancer Center for the treatment of advanced hepatocellular carcinoma (HCC). The regimen integrates systemic immunotherapy with toripalimab (a humanized IgG4 monoclonal antibody targeting PD-1), systemic targeted therapy with lenvatinib (a multi-kinase inhibitor), and localized hepatic arterial infusion chemotherapy (HAIC) using the FOLFOX protocol (oxaliplatin, leucovorin, and 5-fluorouracil). This approach is designed to overcome the limitations of monotherapy in advanced HCC, particularly in patients with high-risk features like portal vein tumor thrombosis (PVTT). Clinical trials, including Phase 2 and Phase 3 studies, have demonstrated that this triple combination significantly improves progression-free survival (PFS) and overall survival (OS) compared to standard-of-care treatments by combining immune activation, anti-angiogenesis, and direct cytotoxic tumor debulking.
- Brand names
- Tuoyi
- Other names
- Toripalimab + Lenvatinib + HAICToripalimab + Lenvatinib + FOLFOX-HAIC
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)DNA
Beyond the preview
Go deeper on toripalimab + lenvatinib + oxaliplatin + leucovorin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + lenvatinib + oxaliplatin + leucovorin + 5-fluorouracil.